Skip to main content
OpenTrials
Completed

NCT Number: NCT05723978

Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer. However, the surgical approach and the extent of resection for patients with pancreatic cancer are controversial at present.

The investigators optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (SED), which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor. The investigators retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. Patients who underwent standard dissection (SD) were matched 2:1 to those who underwent SED using propensity score matching (PSM). The log-rank test and cox regression model were used to analyze survival data. In addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoma, Pancreatic Ductal Adenocarcinoma Carcinoma Carcinoma, Ductal Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Glandular and Epithelial Pancreatic Diseases Pancreatic Neoplasms

Sex eligibility

All sexes

Study type

Observational

Primary location

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 30000, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1) Patients diagnosed as resectable pancreatic cancer were pathologically diagnosed as PDAC after surgery.
  • Patients received radical surgery (R0) and had complete photos or videos of the operation.

Exclusion criteria

  • 1) The operation records as well as related photo or video data could not reflect the surgical approach and the extent of resection.
  • Patients with incomplete clinical, pathological, imaging and follow-up information.

Treatment and study plan

Selective extended dissection of pancreaticoduodenectomy

Procedure

An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.

Primary outcomes

  1. Disease-free survival (DFS)

    Time frame: From the day the patient received surgery to the time the patient was diagnosed with postoperative recurrence, assessed up to 36 months.

Sponsors and collaborators

Lead sponsor

Tianjin Medical University Cancer Institute and Hospital

Other

Registry information

Important dates

Study start
2011
Primary completion
2022
Study completion
2022
First posted
Feb 13, 2023
Registry last updated
Feb 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.